Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study (Q67667083)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

title

Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

main subject

fludarabine phosphate

1 reference

7

S E Salmon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

author name string

E H Kraut

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

J J Crowley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

M R Grever

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

M D Keppen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

J D Bonnet

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

H E Hynes

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

publication date

1 May 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

16 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

page(s)

199-200

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00177259

16 September 2019

exact match

0 references

cites work

Differences in metabolism and cytotoxicity between 9-beta-D arabinofuranosyladenine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in human leukemic lymphoblasts

1 reference

12 December 2020

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

12 December 2020

Pulmonary toxicity associated with fludarabine monophosphate

1 reference

12 December 2020

Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity

1 reference

12 December 2020

Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00177259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1696569%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

16 September 2019

0 references

1 reference